About Curis (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Industry, Sector and Symbol
Trailing P/E Ratio-2.0080538363828
Forward P/E Ratio-1.96
Sales & Book Value
Annual Sales$9.90 million
Price / Sales12.43
Price / CashN/A
Book Value$0.15 per share
Price / Book4.95
Return on Equity-250.55%
Return on Assets-72.61%
Curis (NASDAQ:CRIS) Frequently Asked Questions
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) released its earnings results on Thursday, March, 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.04. The biotechnology company had revenue of $3.26 million for the quarter, compared to analysts' expectations of $2.03 million. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. During the same period in the previous year, the company earned ($0.08) earnings per share. View Curis' Earnings History.
When will Curis make its next earnings announcement?
Where is Curis' stock going? Where will Curis' stock price be in 2018?
2 Wall Street analysts have issued 12 month target prices for Curis' stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Curis' stock price to reach $7.00 in the next year. View Analyst Ratings for Curis.
What are Wall Street analysts saying about Curis stock?
Here are some recent quotes from research analysts about Curis stock:
- 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (2/8/2018)
- 2. Cowen Inc analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)
Are investors shorting Curis?
Curis saw a increase in short interest in February. As of February 15th, there was short interest totalling 3,847,004 shares, an increase of 53.8% from the January 31st total of 2,502,101 shares. Based on an average daily volume of 1,327,013 shares, the short-interest ratio is currently 2.9 days. Currently, 2.9% of the shares of the company are short sold.
Who are some of Curis' key competitors?
Some companies that are related to Curis include Ardelyx (ARDX), Calithera Biosciences (CALA), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), Proteostasis Therapeutics (PTI), Ocular Therapeutix (OCUL), Molecular Templates (MTEM), CTI BioPharma (CTIC), Vital Therapies (VTL), Tyme Technologies (TYME), Athersys (ATHX), Allergy Therapeuti (AGYTF), Compugen (CGEN), CASI Pharmaceuticals (CASI), Verona Pharma plc - American Depositary Share (VRNA), Ra Pharmaceuticals (RARX), Miragen Therapeutics (MGEN) and Synlogic (SYBX).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- James R. McNab Jr., Independent Chairman of the Board (Age 73)
- Ali Fattaey Ph.D., President, Chief Executive Officer, Director (Age 52)
- James E. Dentzer, Chief Financial Officer, Chief Administrative Officer (Age 50)
- David Tuck M.D., Chief Medical Officer (Age 65)
- Lori A. Kunkel M.D., Director (Age 59)
- Martyn D. Greenacre, Independent Director (Age 75)
- Robert E. Martell M.D., Ph.D., Independent Director (Age 54)
- Kenneth J. Pienta M.D., Independent Director (Age 57)
- Marc Rubin M.D., Independent Director (Age 62)
Who owns Curis stock?
Curis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.93%), Millennium Management LLC (1.92%), Baird Financial Group Inc. (1.81%), Renaissance Technologies LLC (0.81%), Two Sigma Investments LP (0.52%) and Goldman Sachs Group Inc. (0.31%). Company insiders that own Curis stock include Ali PhD Fattaey, Discovery Technologie Aurigene, James R Mcnab, Kenneth I Kaitin, Marc Rubin and Martyn D Greenacre. View Institutional Ownership Trends for Curis.
Who sold Curis stock? Who is selling Curis stock?
Who bought Curis stock? Who is buying Curis stock?
Curis' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Goldman Sachs Group Inc., Citadel Advisors LLC, SG Americas Securities LLC and BlackRock Inc.. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey, Discovery Technologie Aurigene and Marc Rubin. View Insider Buying and Selling for Curis.
How do I buy Curis stock?
Shares of Curis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of Curis stock can currently be purchased for approximately $0.74.
How big of a company is Curis?
Curis has a market capitalization of $127.55 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Curis employs 58 workers across the globe.
How can I contact Curis?
Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]
MarketBeat Community Rating for Curis (CRIS)MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Curis (NASDAQ:CRIS) Earnings History and Estimates Chart
Curis (NASDAQ CRIS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018||Q4 2017||($0.09)||($0.05)||$2.03 million||$3.26 million||View||Listen|
|11/7/2017||Q3 2017||($0.09)||($0.11)||$2.19 million||$2.44 million||View||N/A|
|8/3/2017||Q2 2017||($0.09)||($0.10)||$2.08 million||$2.10 million||View||Listen|
|5/4/2017||Q1 17||($0.09)||($0.11)||$1.98 million||$2.13 million||View||Listen|
|3/9/2017||Q4 2016||($0.10)||($0.08)||$1.97 million||$2.40 million||View||Listen|
|11/3/2016||Q316||($0.10)||($0.21)||$1.84 million||$1.80 million||View||Listen|
|8/4/2016||Q216||($0.09)||($0.09)||$2.05 million||$1.70 million||View||Listen|
|5/9/2016||Q116||($0.08)||($0.07)||$2.30 million||$1.70 million||View||Listen|
|2/29/2016||Q415||($0.12)||($0.10)||$2.98 million||$2.10 million||View||Listen|
|11/9/2015||Q315||($0.08)||($0.04)||$2.82 million||$2.00 million||View||N/A|
|8/6/2015||Q215||($0.06)||($0.06)||$3.50 million||$2.10 million||View||N/A|
|5/7/2015||Q115||($0.06)||($0.07)||$2.27 million||$1.17 million||View||N/A|
|2/24/2015||Q4 14||($0.07)||($0.07)||$2.69 million||$2.00 million||View||N/A|
|11/10/2014||Q314||($0.05)||($0.06)||$4.13 million||$1.80 million||View||N/A|
|8/7/2014||Q214||($0.06)||($0.02)||$3.46 million||$4.80 million||View||N/A|
|5/8/2014||Q114||($0.07)||($0.06)||$1.88 million||$1.30 million||View||N/A|
|2/20/2014||Q413||($0.08)||($0.05)||$1.59 million||$1.52 million||View||N/A|
|11/5/2013||Q313||($0.01)||($0.02)||$6.44 million||$7.20 million||View||N/A|
|8/5/2013||Q2 2013||($0.05)||($0.02)||$4.43 million||$5.40 million||View||N/A|
|4/30/2013||Q1 2013||($0.05)||($0.06)||$3.86 million||$0.90 million||View||N/A|
|2/20/2013||Q4 2012||($0.08)||($0.15)||$2.07 million||$1.69 million||View||N/A|
|11/6/2012||Q312||($0.08)||($0.04)||$1.01 million||$0.60 million||View||N/A|
Curis (NASDAQ:CRIS) Earnings Estimates
2018 EPS Consensus Estimate: ($0.31)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com
Curis (NASDAQ CRIS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 48.14%
Curis (NASDAQ CRIS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/16/2017||Marc Rubin||Director||Buy||25,000||$0.98||$24,500.00||51,596|| |
|11/15/2017||Ali Ph.D. Fattaey||CEO||Buy||50,000||$1.06||$53,000.00||115,890|| |
|5/5/2017||James R Mcnab||Director||Sell||76,276||$2.04||$155,603.04||879,688|| |
|5/2/2017||James R Mcnab||Director||Sell||116,708||$2.38||$277,765.04|| |
|4/27/2017||James R Mcnab||Director||Sell||146,694||$2.61||$382,871.34||912,426|| |
|4/24/2017||James R Mcnab||Director||Sell||110,322||$2.59||$285,733.98||1,357,147|| |
|9/7/2016||Discovery Technologie Aurigene||Major Shareholder||Buy||10,208,333||$2.40||$24,499,999.20||27,328,464|| |
|5/27/2016||Martyn D Greenacre||Director||Sell||15,000||$1.69||$25,350.00||40,183|| |
|5/26/2016||Kenneth I Kaitin||Director||Sell||15,000||$1.76||$26,400.00||31,800|| |
|12/30/2015||Daniel R. Passeri||Director||Sell||14,400||$3.01||$43,344.00||198,898|| |
|12/29/2015||Daniel R. Passeri||Director||Sell||11,200||$2.91||$32,592.00||198,898|| |
|12/28/2015||Daniel R. Passeri||Director||Sell||13,600||$2.85||$38,760.00||198,898|| |
|12/23/2015||Daniel R. Passeri||Director||Sell||48,900||$2.78||$135,942.00||198,898|| |
|12/21/2015||Daniel R. Passeri||Director||Sell||289,000||$2.99||$864,110.00||198,898|| |
|8/27/2014||Ali Ph.D. Fattaey||CEO||Buy||62,890||$1.60||$100,624.00|| |
|12/11/2013||Ali Ph.D. Fattaey||COO||Buy||3,000||$2.52||$7,560.00||3,000|| |
|11/12/2013||Michael Gray||CFO||Buy||10,000||$2.86||$28,600.00||107,304|| |
|11/8/2013||Kenneth Pienta||Director||Buy||20,000||$2.95||$59,000.00||30,000|| |
|8/16/2013||James Mcnab||Director||Sell||50,000||$4.00||$200,000.00||1,079,688|| |
|12/6/2012||Daniel R Passeri||CEO||Buy||25,000||$3.03||$75,750.00|| |
Curis (NASDAQ CRIS) News Headlines
|Head-To-Head Contrast: Kura Oncology (KURA) & Curis (CRIS)|
www.americanbankingnews.com - March 17 at 8:07 AM
|Curis, Inc. (CRIS) Expected to Announce Earnings of -$0.08 Per Share|
www.americanbankingnews.com - March 17 at 5:18 AM
|Curis (CRIS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow|
seekingalpha.com - March 15 at 6:03 PM
|What Are Analysts Saying About Curis Inc’s (NASDAQ:CRIS) Earnings Trend?|
finance.yahoo.com - March 15 at 6:03 PM
|Curis (CRIS) Announces Earnings Results, Beats Estimates By $0.04 EPS|
www.americanbankingnews.com - March 9 at 10:35 AM
|Curis Reports Fourth Quarter and Year-End 2017 Financial Results|
finance.yahoo.com - March 8 at 6:31 PM
|Curis Reports Fourth Quarter and Year-End 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - March 8 at 8:30 AM
|Curis to Present at Cowen & Company 38th Annual Health Care Conference - PR Newswire (press release)|
www.prnewswire.com - March 5 at 8:28 AM
|Curis to Present at Cowen & Company 38th Annual Health Care Conference|
finance.yahoo.com - March 5 at 8:27 AM
|Curis, Inc. (CRIS) Sees Significant Growth in Short Interest|
www.americanbankingnews.com - March 3 at 3:26 AM
|Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million|
www.americanbankingnews.com - March 2 at 2:24 PM
|Baird Financial Group Inc. Decreases Stake in Curis, Inc. (CRIS)|
www.americanbankingnews.com - March 2 at 4:42 AM
|Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018 - PR Newswire (press release)|
www.prnewswire.com - March 1 at 8:20 AM
|Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018|
finance.yahoo.com - March 1 at 8:20 AM
|Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - February 28 at 3:32 AM
|Zacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Earnings of -$0.09 Per Share|
www.americanbankingnews.com - February 28 at 3:12 AM
|Curis (CRIS) to Release Earnings on Wednesday|
www.americanbankingnews.com - February 28 at 1:40 AM
|Brokers Offer Predictions for Curis, Inc.'s FY2022 Earnings (CRIS)|
www.americanbankingnews.com - February 22 at 4:34 PM
|Curis (CRIS) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - February 11 at 5:12 PM
|Capstone Turbine Corporation (CPST) and Seadrill Ltd (SDRL) Among Hedge Funds’ Favorite Penny Stocks|
finance.yahoo.com - February 8 at 8:15 AM
|Curis, Inc. (CRIS) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - February 3 at 3:26 AM
|Short Interest in Curis, Inc. (CRIS) Expands By 101.8%|
www.americanbankingnews.com - January 28 at 1:26 AM
|Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share|
www.americanbankingnews.com - January 25 at 1:29 PM
|Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948 - StreetInsider.com|
www.streetinsider.com - January 18 at 10:46 AM
|Curis (CRIS) Reports Initiation of Phase 1 Trial of CA-4948|
www.streetinsider.com - January 17 at 9:45 AM
|Curis Begins Phase 1 Trial Of CA-4948 In Patients With Lymphomas - Quick Facts|
www.nasdaq.com - January 17 at 9:45 AM
|Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma|
finance.yahoo.com - January 17 at 9:45 AM
|Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.03 Million|
www.americanbankingnews.com - January 10 at 5:00 PM
| Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 Earnings Per Share|
www.americanbankingnews.com - January 8 at 9:36 AM
|Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2.03 Million|
www.americanbankingnews.com - December 25 at 10:32 PM
|ETFs with exposure to Curis, Inc. : December 25, 2017|
finance.yahoo.com - December 25 at 6:42 PM
|Want To Invest In Curis Inc (NASDAQ:CRIS)? Here’s How It Performed Lately|
finance.yahoo.com - December 21 at 5:01 PM
|Curis (CRIS) vs. Cellular Dynamics International (ICEL) Financial Survey|
www.americanbankingnews.com - December 16 at 5:16 AM
|Curis, Inc. (CRIS) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - December 15 at 3:32 AM
|ETFs with exposure to Curis, Inc. : December 12, 2017|
finance.yahoo.com - December 12 at 5:24 PM
|-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter|
www.americanbankingnews.com - December 5 at 7:12 AM
|Curis (CRIS) Announces Upcoming Presentation at ASH - StreetInsider.com|
www.streetinsider.com - December 1 at 5:11 PM
|Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition|
finance.yahoo.com - December 1 at 5:11 PM
|ETFs with exposure to Curis, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:58 PM
|Analyzing Curis (CRIS) and Its Competitors|
www.americanbankingnews.com - November 26 at 11:20 AM
|Should You Be Concerned About Curis Inc’s (CRIS) Investors?|
finance.yahoo.com - November 24 at 4:02 PM
|ETFs with exposure to Curis, Inc. : November 20, 2017|
finance.yahoo.com - November 20 at 6:32 PM
|Curis, Inc. (CRIS) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - November 20 at 3:58 AM
| Brokerages Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share|
www.americanbankingnews.com - November 16 at 7:08 PM
|Insider Buying: Curis, Inc. (CRIS) Director Purchases 25,000 Shares of Stock|
www.americanbankingnews.com - November 16 at 5:12 PM
|Ali Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) Stock|
www.americanbankingnews.com - November 15 at 1:30 PM
|3 Things In Biotech You Should Learn Today: November 13, 2017|
seekingalpha.com - November 14 at 2:19 AM
|Curis, Inc. (CRIS) Downgraded by Zacks Investment Research to "Sell"|
www.americanbankingnews.com - November 11 at 7:38 PM
|Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017|
finance.yahoo.com - November 10 at 5:25 PM
|SunTrust Banks Comments on Curis, Inc.'s FY2017 Earnings (CRIS)|
www.americanbankingnews.com - November 10 at 7:47 AM
Curis (NASDAQ:CRIS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Curis (NASDAQ:CRIS) Income Statement, Balance Sheet and Cash Flow Statement
Curis (NASDAQ CRIS) Stock Chart for Saturday, March, 17, 2018